查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011261

隱球菌病治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、患者類型、最終用戶和分銷管道分類）

Cryptococcosis Treatment Market by Drug Class, Administration Route, Patient Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，隱球菌病治療市場價值將達到 82.4 億美元，到 2026 年將成長至 87.1 億美元，到 2032 年將達到 125 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 82.4億美元
預計年份：2026年 87.1億美元
預測年份 2032 125億美元
複合年成長率 (%) 6.12%

一份策略概述，清楚地展現了當今影響隱球菌病治療的臨床複雜性、供應鏈現實和相關人員需求。

隱球菌病是一種具有重要臨床意義的真菌感染疾病，對免疫力缺乏患者的影響尤其顯著，並持續受到臨床醫生、採購負責人和政策制定者的關注。目前，隱球菌病的治療現況受到有效藥物數量有限、給藥途徑複雜、抗藥性模式不斷演變以及合併症管理等因素的限制。因此，相關人員必須在臨床最佳實踐與藥物可近性、給藥途徑以及患者個別因素等實際限制之間取得平衡。

臨床創新、供應鏈重組和管理主導實踐如何共同重新定義隱球菌病治療路徑和相關人員的角色。

隱球菌病的治療格局正在經歷一場變革，這主要得益於藥物治療的進步、監管機構對抗菌藥物合理使用的日益重視以及全球藥品供應鏈的結構性轉變。新型抗真菌製劑和改良的脂質體遞送系統徹底改變了重症疾病的治療選擇。同時，人們也越來越關注抗真菌藥物的合理使用，這促使臨床醫生在住院和門診環境中改進治療方案的順序。此外，製藥公司也在努力應對價格壓力和不斷變化的報銷模式，這些因素正在影響其在產能和製劑創新方面的投資。

本研究評估了 2025 年關稅環境將如何加劇整個抗真菌藥物供應鏈的供應鏈重組、籌資策略和區域製造應對措施。

2025年實施的關稅調整的累積影響暴露了供應鏈中原有的脆弱性，加速了製造商、經銷商和醫療保健系統採取戰略應對措施。活性成分、特殊脂質體輔料和成品藥進口成本的上升加劇了採購預算的壓力，促使終端用戶探索替代籌資策略。為此，製造商正在審查製造地和採購政策，以降低關稅波動帶來的風險，並確保關鍵抗真菌藥物的供應。

將藥物類別、臨床環境、給藥途徑、分銷管道和患者類型與治療和獲取的不同趨勢聯繫起來的詳細細分分析。

細分市場分析揭示了不同治療領域、醫療機構、給藥途徑、分銷管道和患者類型之間的不同趨勢，每種趨勢都對臨床實踐和商業化產生獨特的影響。依藥物類別分類，市場可分為Azole、Flucytosine和Polyenes，並進行深入研究。在Azole類藥物中，市場格局透過Fluconazole、Posaconazole和Voriconazole等特定藥物進行進一步分析。在Polyenes藥物中，去氧膽酸兩性雙性殺黴素B和脂質體兩性雙性殺黴素B製劑均值得關注。這些差異會影響臨床選擇。口服Azole支援長期抑制和門診管理，而Polyenes和Flucytosine在誘導治療和重症疾病通訊協定中發揮核心作用。

區域臨床需求、監管多樣性和製造地如何相互作用並影響全球主要市場的准入、採購和治療方法選擇。

區域趨勢對治療的可近性、採購慣例和臨床管理模式有著至關重要的影響。在美洲，醫院準備和大規模三級醫療中心的存在等政策重點正在塑造對腸外誘導治療的需求，並影響與生產商的合約談判。從住院治療過渡到門診治療是一項關鍵優先事項，這正在重塑臨床醫生和藥劑師管理降階治療和藥物依從性支持的方式。

對正在重塑隱球菌病治療的取得和臨床實施的製藥公司、經銷商和服務供應商進行競爭定位和能力分析。

在該治療領域主要企業憑藉其製劑技術、無菌生產能力、全球分銷網路和合規性脫穎而出。一些製造商正大力投資脂質體製劑技術，以提高耐受性並降低腎毒性，這對於加護病房和移植科室的應用至關重要。另一些製造商則憑藉強大的學名藥產品組合和完善的原料藥成分 (API) 採購體系脫穎而出，從而能夠以具有成本競爭力的價格向門診和資源有限的醫療機構供應藥物。

為領導者提供切實可行的策略建議，以加強供應鏈韌性，使產品組合與臨床路徑保持一致，並最佳化護理過渡各個階段的商業化。

產業領導者應優先考慮一系列切實可行的策略，使臨床優先事項與具有韌性的供應鏈和高度靈活的商業模式一致。首先，採用雙重採購模式生產製造，並投資區域生產能力，可以降低單一來源風險，減輕貿易波動風險。其次，使產品系列與治療路徑要求相匹配，包括確保提供靜脈誘導治療和口服維持治療方案，有助於在住院和門診環境中實現治療的連續性。第三，加強與專科藥局和居家輸液服務提供者的夥伴關係，有助於安全地過渡到後續治療，並提高長期抑制治療的用藥依從性。

為了檢驗實際見解，我們採用透明的混合方法研究途徑，將對臨床醫生和供應鏈相關人員的訪談與監管和技術文獻結合。

本研究整合了一手和二手資料，旨在全面了解臨床實踐、供應鏈動態和商業性行為。一手資料包括對臨床醫生、藥房經理、採購負責人以及製造和分銷部門高管進行結構化訪談，以識別實際挑戰、治療決策因素和採購慣例。這些定性見解輔以對同行評審的臨床文獻、監管指南、產品標籤以及公開的生產和貿易數據的二手分析，以確保技術準確性和背景深度。

簡潔的整合強調製造、臨床實踐和採購等相關人員之間的協作努力，以確保獲得治療並最佳化患者療效。

總之，隱球菌病的治療面臨臨床複雜性和操作脆弱性的雙重挑戰，需要生產者、醫療系統和臨床團隊通力合作。治療方法的選擇受藥物類別、給藥途徑可行性和患者個別因素的影響，而治療的可近性則取決於區域製造地、籌資策略和不斷變化的貿易政策。關稅波動和供應鏈重組帶來的累積壓力凸顯了積極風險管理的必要性，包括採購管道多元化以及住院和門診護理管道之間更緊密的協調。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：隱球菌病治療市場：依藥物類別分類

  • Azole
    • Fluconazole
    • Posaconazole
    • Voriconazole
  • Flucytosine
  • Polyenes
    • 雙性殺黴素B脫氧膽酸鹽
    • 脂質體Amphotericin B

第9章：隱球菌病治療市場（依給藥途徑分類）

  • 靜脈
    • 中央靜脈導管
    • 外圍
  • 口服
    • 懸浮液
    • 藥片

第10章：依患者類型分類的隱球菌病治療市場

  • 愛滋病毒感染者
  • 未感染愛滋病毒的人
    • 正常的免疫功能
    • 移植患者

第11章 隱球菌病治療市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 居家照護
  • 醫院

第12章 隱球菌病治療市場：依分銷管道分類

  • 離線
  • 線上

第13章：隱球菌病治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 隱球菌病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 隱球菌病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國隱球菌病治療市場

第17章：中國隱球菌病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amplyx Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F2G Limited
  • Flynn Pharma Ltd.
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sigmapharm Laboratories LLC
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4316E4E894B8

The Cryptococcosis Treatment Market was valued at USD 8.24 billion in 2025 and is projected to grow to USD 8.71 billion in 2026, with a CAGR of 6.12%, reaching USD 12.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.24 billion
Estimated Year [2026] USD 8.71 billion
Forecast Year [2032] USD 12.50 billion
CAGR (%) 6.12%

A clear and strategic overview that frames the clinical complexity, supply chain realities, and stakeholder imperatives shaping cryptococcosis treatment today

Cryptococcosis remains a clinically significant fungal infection that disproportionately affects immunocompromised populations, prompting sustained attention from clinicians, procurement specialists, and policy makers. The therapeutic landscape is shaped by a limited number of efficacious agents, complex administration requirements, and evolving patterns of resistance and co-morbidity management. As a result, stakeholders must reconcile clinical best practices with real-world constraints such as drug availability, route-of-administration considerations, and patient-specific factors.

In recent years, health systems have reoriented toward more resilient supply chains and closer alignment between hospital formularies and outpatient care pathways. These shifts have influenced prescribing behavior and institutional preparedness, especially in settings that manage high volumes of HIV-infected and transplant patients. Consequently, decision-makers face a dual imperative: ensuring uninterrupted access to first-line and salvage therapies while optimizing outcomes across diverse clinical settings. This introduction frames the core tension between clinical necessity and operational feasibility, establishing the foundation for the more detailed analyses that follow.

How clinical innovation, supply chain reconfiguration, and stewardship-driven practices are jointly redefining cryptococcosis therapy pathways and stakeholder roles

The landscape for cryptococcosis treatment is undergoing transformative shifts driven by advances in pharmacotherapy, regulatory emphasis on antimicrobial stewardship, and structural changes in global pharmaceutical supply chains. Newer antifungal formulations and improved liposomal delivery systems have reshaped treatment options for severe disease, while heightened attention to antifungal stewardship is refining how clinicians sequence therapies across inpatient and outpatient settings. At the same time, manufacturers are adapting to pricing pressures and evolving reimbursement models, which influence investment in manufacturing capacity and formulation innovation.

Technological developments in drug delivery and diagnostics are influencing care pathways. Rapid diagnostics and improved biomarker monitoring enable earlier detection and may alter the duration and intensity of therapy, which in turn affects demand dynamics across administration routes. Parallel to clinical innovation, health systems are prioritizing supplier diversification and inventory resilience, prompting investments in local manufacturing and strategic contracting. Taken together, these dynamics are converging to create a more nuanced, clinically responsive environment for cryptococcosis treatment that requires integrated responses across clinical teams, supply chain managers, and commercial stakeholders.

Assessing how the 2025 tariff environment has intensified supply chain realignment, procurement strategies, and regional manufacturing responses across antifungal supply chains

The cumulative impact of tariff adjustments instituted in 2025 has accentuated pre-existing supply chain vulnerabilities and accelerated strategic responses among manufacturers, distributors, and health systems. Higher import costs for active pharmaceutical ingredients, specialized liposomal excipients, and finished drug products have increased pressure on procurement budgets and encouraged end users to seek alternative sourcing strategies. In response, manufacturers have re-evaluated their manufacturing footprints and sourcing policies to mitigate exposure to tariff volatility and to preserve access to critical antifungal agents.

Consequently, some suppliers have accelerated localization and dual-sourcing initiatives, investing in regional production hubs and qualifying additional contract manufacturers to maintain continuity of supply. These actions reduce single-source exposure but require capital expenditure, regulatory approvals, and time to qualify new facilities. For purchasers, the tariff landscape has prompted more stringent supplier performance monitoring and an increased use of long-term agreements with price-stability mechanisms. Clinicians and pharmacy leaders have also revisited inventory policies, balancing just-in-time procurement with strategic buffer stocks to manage short-term disruptions. Overall, the tariff environment has served as a catalyst for structural change, encouraging stakeholders to adopt more resilient, albeit sometimes costlier, approaches to ensuring uninterrupted access to treatment.

In-depth segmentation insights tying drug classes, clinical settings, administration routes, distribution channels, and patient types to differentiated treatment and access dynamics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, care settings, administration routes, distribution channels, and patient types, each of which carries distinct implications for clinical practice and commercialization. Based on drug class, the market is studied across Azoles, Flucytosine, and Polyenes; within Azoles, the landscape is further examined through specific agents such as Fluconazole, Posaconazole, and Voriconazole, while Polyenes merit attention for both Amphotericin B Deoxycholate and Liposomal Amphotericin B formulations. These distinctions inform clinical choice, as oral azoles support long-term suppression and outpatient management, whereas polyene formulations and flucytosine are central to induction and severe disease protocols.

Based on End User, the market is studied across Clinics, Home Care, and Hospitals; Clinics are further differentiated into Outpatient Clinics and Specialist Clinics, reflecting where patients interface with structured monitoring and initiation of therapy. Based on Administration Route, the market is studied across Intravenous and Oral; Intravenous administration is further parsed into Central Line and Peripheral options, while Oral delivery is evaluated by Suspension and Tablet formulations. These nuances affect logistics, nursing resource allocation, and patient adherence strategies. Based on Distribution Channel, the market is studied across Offline and Online, highlighting the growing role of e-commerce and specialty pharmacy channels in improving outpatient access. Finally, based on Patient Type, the market is studied across HIV Infected and Non-HIV Infected populations; Non-HIV Infected groups are further segmented into Immunocompetent and Transplant Patients, each presenting distinct comorbidity profiles and therapeutic risk-benefit calculations. Integrating these segmentation lenses enables a granular understanding of usage patterns, formulary decisions, and the operational trade-offs that guide therapy selection across care settings.

How regional clinical imperatives, regulatory diversity, and manufacturing footprints interact to shape access, procurement, and treatment choices across major global markets

Regional dynamics exert a decisive influence on treatment availability, procurement practices, and clinical management paradigms. In the Americas, policy emphasis on hospital preparedness and the presence of large tertiary care centers shape demand for parenteral induction therapies and influence contract negotiations with manufacturers. Transitioning care from inpatient to outpatient settings is a key priority, and this reshapes how clinicians and pharmacists manage step-down therapy and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable health infrastructure create a mosaic of access realities. Countries with advanced diagnostics and reimbursement pathways have adopted newer formulations more rapidly, while resource-constrained settings prioritize cost-effective, readily available agents and pragmatic protocols that account for limited inpatient capacity. Cross-border procurement and donor-supported supply channels remain important in many jurisdictions. In the Asia-Pacific region, manufacturing capacity, particularly for generic azoles and certain APIs, is concentrated in a handful of producer countries, influencing regional supply dynamics and pricing. At the same time, several health systems are investing in diagnostic capacity and regional distribution networks to improve early detection and outpatient continuity of care. These regional patterns highlight the need for strategies tailored to local regulatory, clinical, and supply-chain contexts, while acknowledging the transnational nature of manufacturing and distribution interdependencies.

Competitive positioning and capability analysis of manufacturers, distributors, and service providers that are reshaping therapeutic access and clinical adoption in cryptococcosis care

Key companies operating in this therapeutic area are differentiated by their capabilities in formulation expertise, sterile manufacturing, global distribution networks, and regulatory compliance. Some manufacturers have invested heavily in liposomal formulation technology to improve tolerability and reduce nephrotoxicity, which has implications for uptake in intensive care and transplant units. Other firms have differentiated through robust generics portfolios and extensive API sourcing arrangements that support cost-competitive supply to outpatient and resource-constrained settings.

Distributors and specialty pharmacies play a pivotal role in bridging hospital and community care, particularly where complex intravenous therapies transition to home infusion or ambulatory infusion centers. Clinical service providers and contract manufacturers that can ensure consistent quality, scalable production, and accelerated regulatory filing pathways are increasingly valuable partners. In addition, diagnostic and digital health firms that enable earlier detection and remote monitoring contribute to more efficient treatment pathways. Overall, organizational strength is defined by the ability to integrate clinical evidence, manufacturing reliability, and responsive commercial models to support both acute-care induction and long-term suppression strategies across diverse patient populations.

Actionable strategic recommendations for leaders to strengthen supply resilience, align portfolios with clinical pathways, and optimize commercialization across care transitions

Industry leaders should prioritize a set of actionable strategies that align clinical priorities with resilient supply and adaptive commercial models. First, investing in manufacturing dual-sourcing and regional production capacity will reduce single-source risk and mitigate trade-related volatility. Second, aligning product portfolios with care pathway requirements-such as ensuring availability of both intravenous induction options and oral consolidation therapies-will support continuity across inpatient and outpatient settings. Third, strengthening partnerships with specialty pharmacies and home-infusion providers will facilitate safe transitions of care and improve adherence for long-term suppression regimens.

Moreover, leaders should embed robust stewardship and diagnostics into their commercialization plans to support appropriate use and to protect clinical efficacy. Contracting strategies that include price-stability clauses, inventory sharing arrangements, and outcomes-linked agreements can stabilize procurement budgets while maintaining access. Finally, targeted investments in clinician education, formulary support, and patient adherence programs will accelerate uptake in appropriate settings and improve outcomes. Collectively, these recommendations provide a pragmatic blueprint for converting strategic insight into operational resilience and improved patient care.

A transparent mixed-methods research approach combining clinician and supply-chain interviews with regulatory and technical literature to validate actionable insights

This research synthesizes primary and secondary inputs to produce a comprehensive understanding of clinical practice, supply-chain dynamics, and commercial behaviors. Primary research included structured interviews with clinicians, pharmacy directors, procurement officers, and manufacturing and distribution executives to capture real-world operational challenges, therapeutic decision drivers, and procurement practices. These qualitative insights were supplemented by secondary analysis of peer-reviewed clinical literature, regulatory guidance, product labels, and public-domain manufacturing and trade data to ensure technical accuracy and contextual depth.

Triangulation methods were applied to reconcile divergent perspectives and to validate recurring patterns across geographies and care settings. Where appropriate, regulatory timelines and manufacturing capacity constraints were mapped against clinical treatment protocols to identify potential bottlenecks and points of intervention. The methodology prioritized transparency in assumptions and robustness in cross-validation to ensure that conclusions reflect observable trends and expert judgment rather than speculative projection.

A concise synthesis emphasizing coordinated action across manufacturing, clinical, and procurement stakeholders to secure treatment access and optimize patient outcomes

In summary, cryptococcosis treatment is situated at the intersection of clinical complexity and operational fragility, requiring coordinated action across manufacturers, health systems, and clinical teams. Therapeutic choices hinge on drug class selection, administration route feasibility, and patient-specific factors, while access is shaped by regional manufacturing footprints, procurement strategies, and evolving trade policies. The cumulative pressures from tariff shifts and supply-chain realignments underscore the necessity of proactive risk management, including diversified sourcing and closer integration between inpatient and outpatient care channels.

Looking ahead, organizations that invest in resilient manufacturing, targeted clinical education, robust stewardship, and strategic partnerships will be best positioned to sustain access and improve clinical outcomes. By translating analytical insight into pragmatic interventions-ranging from contracting innovations to diagnostic-enabled care pathways-stakeholders can navigate the complex landscape more effectively and ensure that patients receive timely, evidence-based therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cryptococcosis Treatment Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Posaconazole
    • 8.1.3. Voriconazole
  • 8.2. Flucytosine
  • 8.3. Polyenes
    • 8.3.1. Amphotericin B Deoxycholate
    • 8.3.2. Liposomal Amphotericin B

9. Cryptococcosis Treatment Market, by Administration Route

  • 9.1. Intravenous
    • 9.1.1. Central Line
    • 9.1.2. Peripheral
  • 9.2. Oral
    • 9.2.1. Suspension
    • 9.2.2. Tablet

10. Cryptococcosis Treatment Market, by Patient Type

  • 10.1. HIV Infected
  • 10.2. Non-HIV Infected
    • 10.2.1. Immunocompetent
    • 10.2.2. Transplant Patients

11. Cryptococcosis Treatment Market, by End User

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialist Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cryptococcosis Treatment Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Cryptococcosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cryptococcosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cryptococcosis Treatment Market

17. China Cryptococcosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amplyx Pharmaceuticals, Inc.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Bausch Health Companies Inc.
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Ltd.
  • 18.11. F2G Limited
  • 18.12. Flynn Pharma Ltd.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. Glenmark Pharmaceuticals Limited
  • 18.15. Janssen Pharmaceuticals, Inc.
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. NuCare Pharmaceuticals, Inc.
  • 18.20. Pfizer Inc.
  • 18.21. Sigmapharm Laboratories LLC
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)